Contact this trialFirst, we need to learn more about you.
KRAS G12C Inhibitor
Adagrasib + Olaparib for Solid Tumors
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a combination of two drugs, adagrasib and olaparib, in patients with advanced solid tumors that have specific genetic mutations. The goal is to find a safe dose and see if the combination can effectively block cancer growth and prevent cancer cells from repairing themselves. Olaparib has shown activity in various cancers, particularly those with certain genetic mutations.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service